Document is current
Any future updates will be listed below
-
Authors
Laubach, Jacob P. http://orcid.org/0000-0001-7565-2052
Tuchman, Sascha A. http://orcid.org/0000-0003-2109-1573
Rosenblatt, Jacalyn M.
Mitsiades, Constantine S.
Colson, Kathleen
Masone, Kelly
Warren, Diane
Redd, Robert A. http://orcid.org/0000-0002-1329-5288
Grayson, Dena http://orcid.org/0000-0003-2818-8458
Richardson, Paul G. http://orcid.org/0000-0002-7426-8865
- License Information
-
More Information
Article History
Received: 21 July 2020
Revised: 8 December 2020
Accepted: 23 December 2020
First Online: 5 February 2021
Conflict of interest
: J.P.L., J.M.R., K.C., K.M., D.W., and R.A.R. report no conflicts of interest. S.A.T. reports grants and personal fees from Celgene, grants and personal fees from Karyopharm, grants and personal fees from Sanofi, personal fees from Caelum, grants from Amgen, and grants from Janssen, outside the submitted work. C.S.M. discloses employment of a relative with Takeda; consultant/honoraria from Fate Therapeutics, Ionis Pharmaceuticals; past research funding from Novartis; as well as research funding outside the scope of this submitted work from Janssen/Johnson & Johnson, TEVA, EMD Serono, AbbVie, Karyopharm, Sanofi, and Arch Oncology. D.G. is a consultant to Secura Bio, Inc. P.G.R. reports grants from BMS, grants and honoraria (advisory committee member) from Oncopeptides, Celgene, Takeda, and Karyopharm; and honoraria (advisory committee member) from Janssen, Sanofi, and Secura Bio, Inc. outside the submitted work.
